Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
A phase 2 trial of TAS-120 in biliary tract cancer, run by Taiho Oncology, Inc., now recruiting.
Overview
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement is a phase 2 interventional study registered as NCT05727176 by Taiho Oncology, Inc., with 120 participants planned, started 2023-07-05 and due to reach its primary completion in 2026-12. Interventions recorded: TAS-120.
Similar pages
not linked directly; found by shared links- TrialStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialA Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialPhase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Shares Araris Biotech (Taiho) and the tag pipeline.
- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialFutibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Shares Araris Biotech (Taiho), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.